FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120429477> ?p ?o ?g. }

• W3120429477 endingPage "S42" @default.
• W3120429477 startingPage "S42" @default.
• W3120429477 abstract "Abstract Background Herpes zoster (HZ) is common after allogeneic hematopoietic stem cell transplantation (HCT) and associated with high morbidity. While antiviral prophylaxis reduces incidence, increased risk remains after discontinuation and vaccination strategies are needed. A non-live adjuvanted recombinant zoster vaccine (RZV) has been developed but not yet studied in this population. Methods In this single center prospective observational cohort study, allogeneic HCT recipients ³18 years old and 9–24 months from HCT were eligible to receive 2 doses of RZV separated by ³8 weeks as part of revised institutional vaccination guidelines. The primary endpoint was safety and reactogenicity in the total vaccinated cohort (TVC). The secondary endpoints were incidence and severity of chronic graft versus host disease (cGVHD) in the TVC compared to historical controls and incidence rates of HZ in the TVC and modified total vaccinated cohort (mTVC). Results Of the 158 participants (mean age 55 years, 91 [58%] male) in the TVC, 150 (95%) received second vaccine. 92.1% had solicited reactions with 87.3% injection site reactions (18.7% grade 3) and 82.8% general reactions (26.5% grade 3). In the subgroup receiving first vaccine at 9–12 months after HCT, cumulative incidence of cGVHD was similar to historical controls at predefined time points between 9–15 months (unadjusted incidence rate ratio [IRR] 1.1 [95% CI 0.84–1.44], adjusted IRR 1.05 [95% CI 0.8–1.38]); there was also no difference in severity of cGVHD, or incidence of death or disease relapse. There were 4 (2.5%) HZ cases during the study period with IR 28.34/1000 person-years over median follow up 281 days (IQR 190, 354) in the mTVC. All cases occurred after antiviral prophylaxis discontinuation and one case resulted in death. Conclusion Two doses of RZV after allogeneic HCT was safe and acceptable despite high rates of reactogenicity. There was no evidence of an increase in cGVHD, relapse, or death compared to historical controls and overall low rates of breakthrough HZ similar to those reported after autologous HCT. Immunogenicity studies and placebo-controlled trials are needed to determine vaccine response and efficacy so that timing of RZV and its potential impact on discontinuation of antiviral prophylaxis can be determined. Disclosures Nicolas C. Issa, MD, AiCuris (Scientific Research Study Investigator)Astellas (Scientific Research Study Investigator)GSK (Scientific Research Study Investigator)Merck (Scientific Research Study Investigator)" @default.
• W3120429477 created "2021-01-18" @default.
• W3120429477 creator A5000363583 @default.
• W3120429477 creator A5031812464 @default.
• W3120429477 creator A5044205225 @default.
• W3120429477 creator A5050536718 @default.
• W3120429477 creator A5064126602 @default.
• W3120429477 creator A5080601053 @default.
• W3120429477 creator A5091029647 @default.
• W3120429477 creator A5091338614 @default.
• W3120429477 date "2020-10-01" @default.
• W3120429477 modified "2023-09-26" @default.
• W3120429477 title "36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation" @default.
• W3120429477 doi "https://doi.org/10.1093/ofid/ofaa439.081" @default.
• W3120429477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7776116" @default.
• W3120429477 hasPublicationYear "2020" @default.
• W3120429477 type Work @default.
• W3120429477 sameAs 3120429477 @default.
• W3120429477 citedByCount "0" @default.
• W3120429477 crossrefType "journal-article" @default.
• W3120429477 hasAuthorship W3120429477A5000363583 @default.
• W3120429477 hasAuthorship W3120429477A5031812464 @default.
• W3120429477 hasAuthorship W3120429477A5044205225 @default.
• W3120429477 hasAuthorship W3120429477A5050536718 @default.
• W3120429477 hasAuthorship W3120429477A5064126602 @default.
• W3120429477 hasAuthorship W3120429477A5080601053 @default.
• W3120429477 hasAuthorship W3120429477A5091029647 @default.
• W3120429477 hasAuthorship W3120429477A5091338614 @default.
• W3120429477 hasBestOaLocation W31204294771 @default.
• W3120429477 hasConcept C120665830 @default.
• W3120429477 hasConcept C121332964 @default.
• W3120429477 hasConcept C126322002 @default.
• W3120429477 hasConcept C141071460 @default.
• W3120429477 hasConcept C187212893 @default.
• W3120429477 hasConcept C203014093 @default.
• W3120429477 hasConcept C203092338 @default.
• W3120429477 hasConcept C22070199 @default.
• W3120429477 hasConcept C2777408962 @default.
• W3120429477 hasConcept C2777704310 @default.
• W3120429477 hasConcept C2778715236 @default.
• W3120429477 hasConcept C2780868878 @default.
• W3120429477 hasConcept C2908647359 @default.
• W3120429477 hasConcept C2911091166 @default.
• W3120429477 hasConcept C535046627 @default.
• W3120429477 hasConcept C61511704 @default.
• W3120429477 hasConcept C71924100 @default.
• W3120429477 hasConcept C72563966 @default.
• W3120429477 hasConcept C88879693 @default.
• W3120429477 hasConcept C8891405 @default.
• W3120429477 hasConcept C99454951 @default.
• W3120429477 hasConceptScore W3120429477C120665830 @default.
• W3120429477 hasConceptScore W3120429477C121332964 @default.
• W3120429477 hasConceptScore W3120429477C126322002 @default.
• W3120429477 hasConceptScore W3120429477C141071460 @default.
• W3120429477 hasConceptScore W3120429477C187212893 @default.
• W3120429477 hasConceptScore W3120429477C203014093 @default.
• W3120429477 hasConceptScore W3120429477C203092338 @default.
• W3120429477 hasConceptScore W3120429477C22070199 @default.
• W3120429477 hasConceptScore W3120429477C2777408962 @default.
• W3120429477 hasConceptScore W3120429477C2777704310 @default.
• W3120429477 hasConceptScore W3120429477C2778715236 @default.
• W3120429477 hasConceptScore W3120429477C2780868878 @default.
• W3120429477 hasConceptScore W3120429477C2908647359 @default.
• W3120429477 hasConceptScore W3120429477C2911091166 @default.
• W3120429477 hasConceptScore W3120429477C535046627 @default.
• W3120429477 hasConceptScore W3120429477C61511704 @default.
• W3120429477 hasConceptScore W3120429477C71924100 @default.
• W3120429477 hasConceptScore W3120429477C72563966 @default.
• W3120429477 hasConceptScore W3120429477C88879693 @default.
• W3120429477 hasConceptScore W3120429477C8891405 @default.
• W3120429477 hasConceptScore W3120429477C99454951 @default.
• W3120429477 hasIssue "Supplement_1" @default.
• W3120429477 hasLocation W31204294771 @default.
• W3120429477 hasLocation W31204294772 @default.
• W3120429477 hasLocation W31204294773 @default.
• W3120429477 hasOpenAccess W3120429477 @default.
• W3120429477 hasPrimaryLocation W31204294771 @default.
• W3120429477 hasRelatedWork W1473782864 @default.
• W3120429477 hasRelatedWork W2004368639 @default.
• W3120429477 hasRelatedWork W2042380991 @default.
• W3120429477 hasRelatedWork W2044058499 @default.
• W3120429477 hasRelatedWork W2147261346 @default.
• W3120429477 hasRelatedWork W2187707794 @default.
• W3120429477 hasRelatedWork W2360260519 @default.
• W3120429477 hasRelatedWork W2409957712 @default.
• W3120429477 hasRelatedWork W4306253774 @default.
• W3120429477 hasRelatedWork W4319741939 @default.
• W3120429477 hasVolume "7" @default.
• W3120429477 isParatext "false" @default.
• W3120429477 isRetracted "false" @default.
• W3120429477 magId "3120429477" @default.
• W3120429477 workType "article" @default.